Boston Scientific Corporation $BSX Shares Sold by Courier Capital LLC

Courier Capital LLC trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 54.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,570 shares of the medical equipment provider’s stock after selling 19,934 shares during the quarter. Courier Capital LLC’s holdings in Boston Scientific were worth $723,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA purchased a new stake in Boston Scientific during the second quarter valued at about $2,156,233,000. Jupiter Topco LLC purchased a new stake in Boston Scientific during the second quarter valued at about $803,357,000. Bank of America Corp DE acquired a new position in shares of Boston Scientific in the second quarter worth about $556,026,000. Finally, Legal & General Group Plc acquired a new position in shares of Boston Scientific in the second quarter worth about $431,890,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Rothschild & Co Redburn decreased their price objective on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 23rd. Finally, Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $68.43.

Boston Scientific Stock Down 1.2%

NYSE BSX traded down $0.51 during trading on Tuesday, reaching $43.33. 14,273,273 shares of the company’s stock were exchanged, compared to its average volume of 18,649,461. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a fifty-two week low of $41.38 and a fifty-two week high of $105.65. The company’s fifty day simple moving average is $46.47 and its 200-day simple moving average is $50.35. The firm has a market capitalization of $62.79 billion, a PE ratio of 17.54, a P/E/G ratio of 1.03 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.25 EPS for the current year.

Insider Activity at Boston Scientific

In related news, Director David Habiger acquired 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.